Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohngs disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohngs disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders. © The Author(s), 2010.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below